the operating grant: evaluation of interventions to address the opioid crisis funding opportunity is expected to:

• address the pressing intervention-related evidence needs of knowledge users within one or more pillars of the cdss.
• increase the application of knowledge in health care and/or health services policy and practice related to one or more pillars of the cdss, in order to address the most urgent elements of the opioid crisis, including opioid-related mortality rates.
• encourage the evaluation of interventions that consider sub-populations and/or the biological and social determinants of problematic opioid use

the objective of this funding opportunity is to catalyze and support research efforts of canadian researchers to use the available clsa data in order to better understand how (individually and in combination) the biological, medical, psychological, social, lifestyle and/or economic aspects of people’s lives have an impact in both maintaining health and in the development of disease and disability as people age.

fy18 prp program announcements and general application instructions for the following award mechanisms are a posted on grants.gov.  .

applications to the fy18 prp are being solicited by the u.s. army medical research acquisition activity. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

important:  the prp seeks to focus applications and direct funding by providing focus areas to address the critical needs in parkinson’s disease research. 

http://cdmrp.army.mil/funding/prp

investigator-initiated research award – letter of intent due september 17, 2018

assistant professor level or above (or equivalent)

·        supports highly rigorous, multi-disciplinary, high-impact research projects that have the potential to make an important contribution to parkinson’s disease research and/or patient care.

·        potential impact of research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

·        must address at least one of the fy18 prp iira focus areas.

·        preliminary data to support feasibility are encouraged.

·        submission of a letter of intent is required prior to full application submission.

·        clinical trials are not allowed.

partnering pi option:

·        provides a higher level of funding to support synergistic partnerships between two or three independent investigators collaborating on a single application.

·        principal investigators (pis) are expected to demonstrate within the application the synergistic components that will significantly advance the project, such that the research outcomes could not otherwise be accomplished through the independent efforts of a single pi.

individual pi:

·       maximum funding of $1.5 million (m) for total costs (includes direct and indirect costs).

·       maximum period of performance is 3 years.

partnering pi option:

o    maximum funding of $2m for total costs (includes direct and indirect costs).

o    maximum period of performance is 3 years.

early investigator research award - letter of intent due september 17, 2018

investigator must be a postdoctoral or clinical fellow, instructor, or assistant professor within 5 years of advanced degree or residency training (or equivalent).

·         supports early-career investigators who have innovative, high-impact ideas or new technologies applicable to parkinson’s disease research and/or patient care.

·         pis must have a designated mentor who is an experienced parkinson’s disease researcher.

·         must address the fy18 prp eira focus area.

·        preliminary data are not required.

·        submission of a letter of intent is required prior to full application submission.

·        clinical trials are not allowed.

·         maximum funding of $340,000 for total costs (includes direct and indirect costs).

·         maximum period of performance is 2 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the fy18 defense appropriations act provides $100 million (m) to the department of defense prostate cancer research program (pcrp) to support innovative, high-impact prostate cancer research. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, research, development, and acquisition (dha rda) directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

fy18 pcrp program announcements and general application instructions for the following award mechanisms are posted on grants.gov. 

the mission of the pcrp is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of service members, veterans, and all men experiencing the impact of the disease.  applications submitted to the fy18 pcrp must addresses one or more of the overarching challenges (revised for fy18):

·         develop treatments that improve outcomes for men with lethal prostate cancer

·         reduce lethal prostate cancer in african americans, veterans, and other high-risk populations

·         define the biology of lethal prostate cancer to reduce death

·         improve the quality of life for survivors of prostate cancer

http://cdmrp.army.mil/funding/pcrp

health disparity research award – letter of intent due september 20, 2018

• established investigators:  independent investigators at or above the level of assistant professor (or equivalent)
• or new investigators:  investigators that meet the following criteria at the application submission deadline date:

·         have the freedom to pursue individual aims without formal mentorship

·         have not previously received a pcrp health disparity research award and/or idea development award

• have completed at least 3 years of postdoctoral training or fellowship and are within 10 years after completion of a terminal degree (excluding residency or family medical leave)

·         supports new ideas for prostate cancer research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 

·         research ideas should be innovative, but primary emphasis will be placed on the potential impact of the proposed work.

·         preliminary data are encouraged, but not required.

• proposed projects may include basic, translational, or clinical research, including clinical trials.
• must address at least one of the fy18 pcrp overarching challenges.
• new investigator option supports applicants early in their faculty appointments or in the process of developing independent research careers.

·         established investigators:

·         maximum funding of $1,000,000 for direct costs (plus indirect costs).

·         new investigators:

·         maximum funding of $600,000 for direct costs (plus indirect costs).

• maximum period of performance is 3 years.

health disparity scholar award – letter of intent due bu september 20, 2018

by march 31, 2019

postdoctoral ph.d. or m.d. pis:

• must have successfully defended a doctoral thesis or possess an m.d. degree
• have 3 years or less of postdoctoral research experience

·         supports research opportunities focused on reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality for individuals in the early stages of their careers.

• pis must have a designated mentor who is an experienced prostate cancer researcher.
• must address at least one of the fy18 pcrp overarching challenges.

·         maximum funding of $200k for direct costs (plus indirect costs).

• maximum period of performance is 2 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the pcrp or other cdmrp-administered programs, please visit the cdmrp website.

point of contact:

cdmrp help desk

301-682-5507
help@ebrap.org      

the nserc awards for science promotion honour individuals and groups who make an outstanding contribution to the promotion of science in canada through activities encouraging popular interest in science or developing science abilities. two recipients (one individual and one group) may be selected for the awards each year.

as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp).

the mission of the prorp is to address the most significant gaps in care for the leading burden of injury for facilitating return-to-duty by funding innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries sustained during combat and combat-related activities. 

prolonged field care (pfc) has been identified as the number one capability gap across the army.  pfc includes field trauma care extended beyond doctrinal timelines until the patient can be transported from the point of injury to an appropriate level of care.  in order to address this gap and prepare the orthopaedic field for the next conflict or mass event, the fy18 prorp has identified several orthopaedic areas of focus for funding that will support patient care closer to the point of injury and to allow patients to more quickly return to duty/work. 

the prorp will solicit research applications that specifically address at least one of the following fy18 focus areas:

o    animal models - develop animal models that replicate prolonged field care-related injuries, including ischemia reperfusion injury and compartment syndrome.

o    device development - develop offloading and stability devices (e.g., braces, casting) for ligamentous injuries, small extremity fractures, and /or other non-severe common battlefield musculoskeletal injuries for immediate return to duty.

o    wound infection – evaluate and /or translate promising available clinical interventions in prevention and control of combat extremity wound infections (e.g., for long bone open fractures) to improve their durability to treat service member injuries as close as possible to the point of injury.  projects that further develop novel wound protectants for this population will also be considered.

o    treatment techniques and outcomes - develop and /or evaluate optimal non-surgical and /or surgical treatment strategies and intervention delivery parameters (e.g., frequency, intensity, time, and intervention type) to rapidly remediate duty-limiting  impairments, functional limitations, or barriers to full duty readiness following orthopedic injuries.  interventions may include, but are not limited to:  combination therapies (simultaneous application of multiple treatment modalities), injections, dry needling, manual therapy, therapeutic exercise, or other techniques to return service members to duty within 72 hours.

o    surgical care - translate early research findings, in any of the below surgical care areas, to humans.

§  surgical care areas: peripheral nerve injuries, prevention of heterotopic ossification, volumetric muscle loss, extremity fractures, pelvic ring injuries, compartment syndrome, gaps in clinical practice guidelines (http://www.usaisr.amedd.army.mil/cpgs.html), surgical techniques to optimize gait, soft tissue trauma, osteoarthritis

o    surgical techniques and outcomes - evaluate optimal surgical treatment strategies, tools, and delivery parameters to improve functional outcomes of service members who have sustained orthopaedic injuries.  the proposed research should address at least one topic from the surgical care areas (listed below), and strategies to return the patient to duty and potentially shorten recovery in theater.

§  surgical care areas: peripheral nerve injuries, prevention of heterotopic ossification, volumetric muscle loss, extremity fractures, pelvic ring injuries, compartment syndrome, gaps in clinical practice guidelines (http://www.usaisr.amedd.army.mil/cpgs.html), surgical techniques to optimize gait, soft tissue trauma, osteoarthritis

o    rehabilitation techniques and outcomes – evaluate optimal rehabilitation treatment strategies, tools, and delivery parameters to improve functional outcomes for immediate return to duty of service members who have sustained orthopaedic injuries. 

o    acute pain - evaluate promising available or emerging clinical interventions to control acute pain (e.g., analgesics, anti-inflammatory agents, nerve blocks) following orthopaedic injuries in the pre-hospital setting.  projects that investigate a pathway to enhance non-physician capabilities to deliver rapid, long lasting, analgesia with minimal cognitive side effects in an austere environment are encouraged.

o    improved surgical interventions - develop or optimize orthopaedic surgical interventions to support their use in the pre-hospital environment.

o    tissue regeneration:

§  development and preclinical testing of therapies for volumetric muscle loss due to traumatically damaged tissues of the extremities. 

§  develop and /or evaluate regenerative medicine therapies (devices, drugs, biologics, and /or techniques) for traumatically injured tissues of the extremities.

§  evaluate advanced regenerative medicine therapeutics for restoration of traumatically injured extremity tissues.

the following fy18 prorp award mechanisms are released (note that focus area requirements vary by award mechanism):

http://cdmrp.army.mil/funding/prorp

applied research award – preproposal due july 30, 2018

·         independent investigators at all academic levels (or equivalent) are eligible to submit applications.

·         pre-application is required; full application submission is by invitation only.

·         supports applied research applications focused on advancing optimal treatment and restoration of function for military personnel with musculoskeletal injuries sustained during combat or combat-related activities.

·         proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.

·         clinical trials are not allowed under this award mechanism.

·         applications must address one the following fy18 prorp focus areas:

o   animal models

o    device development

o    wound infection

o    tissue regeneration

·         maximum funding of $750,000 for total costs.

·         maximum period of performance is 3 years.

clinical trial award – preproposal due july 30, 2018

·         independent investigators at all academic levels (or equivalent) are eligible to submit applications.

·         pre-application is required; full application submission is by invitation only.

·         supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries, or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates.

·         funding must support a clinical trial and may not be used for preclinical research studies.

·         collaboration with military researchers and clinicians is encouraged.

·         studies that include active duty military or veteran participants as all or a portion of the study population will be considered.

·         investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration within 6 months of the award date.

·         applications must address one the following fy18 prorp focus areas:

o   surgical techniques and outcomes

o    rehabilitation techniques and outcomes

o    acute pain

o    improved surgical interventions

o    tissue regeneration

·         maximum funding of $3 million (m) for direct costs (plus indirect costs).

·         maximum period of performance is 4 years.

clinical translational research award – preproposal due july 30, 2018

·         independent investigators at all academic levels (or equivalent) are eligible to submit applications.

·         pre-application is required; full application submission is by invitation only.

·         supports high-impact and/or emerging research that may or may not be ready for a full scale randomized controlled clinical trial.

·         funding must support clinical research studies involving humans.

·         preliminary or published data relevant to the proposed research project are required.

·         collaboration with military researchers and clinicians is encouraged.

·         studies that include active duty military or veteran participants as all or a portion of the study population will be considered.

·         investigational new drug or investigational device exemption applications, if needed, should be submitted to the food and drug administration within 6 months of the award date.

·         applications must address one the following fy18 prorp focus areas:

o   treatment techniques and outcomes

o    wound infection

o    surgical care

o    tissue regeneration

·         maximum funding of $2m for direct costs (plus indirect costs),

·         maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

applications must be submitted through the federal government’s single-entry portal, grants.gov.  for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the prorp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

nserc's promoscience program offers financial support for organizations working with young canadians to promote an understanding of science and engineering (including mathematics and technology). organizations may request funds for up to three years at a time.

promoscience supports hands-on learning experiences for young 世界杯2022赛程表淘汰赛 and their teachers. grants may be used to cover improvements to program content or delivery, as well as for new programs and activities. grants can also be used to cover operational costs such as salaries, travel, postage, materials and supplies, provided that they relate to the promotion of science and engineering.

the fy18 defense appropriation provides $10 million (m) to the department of defense orthotics and prosthetics outcomes research program (oporp) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for service members and veterans who have undergone limb amputation.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program research, development, test, and evaluation appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy18 oporp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov. 

oporp awards are focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology.  the intent of the awards is to generate clinically useful evidence that will enhance and optimize patient outcomes.

focus areas:  the oporp will only consider applications that specifically address the critical needs of the orthotics and prosthetics outcomes research community in one or more of the fy18 focus areas.  the oporp will solicit research applications that address at least one of the following fy18 focus areas:

• orthotic or prosthetic device form:  understand patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
• orthotic or prosthetic device fit:  understand patient outcomes related to human-device interface and component connection through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
• orthotic or prosthetic device function:  understand patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

http://cdmrp.army.mil/funding/oporp

clinical research award – preproposal due august 6, 2018

• independent investigators at all academic levels (or equivalent)
• supports research that evaluates the comparative effectiveness of orthotic and/or prosthetic clinical interventions using patient-centric outcomes for service members and veterans with limb loss and/or limb impairment.
• proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
• collaboration among academia, industry, the dod, and the department of veterans affairs (va) is highly encouraged, including longitudinal outcomes studies.
• applications submitted to the fy18 oporp cra must address one or more of the fy18 oporp focus areas.
• animal studies are not allowed.
• clinical trials are not allowed.
• preproposal submission is required; application submission is by invitation only.

·         funding level 1:

o   maximum funding of $350,000 for total costs (direct costs plus indirect costs)

o   maximum period of performance is 2 years.

·         funding level 2:

o   maximum funding of $1,500,000 for total costs (direct costs plus indirect costs)

• maximum period of performance is 4 years.

clinical trial award – preproposal due august 6, 2018

independent investigators at all academic levels (or equivalent)

·         supports rapid implementation of clinical trials with the potential to make significant impacts on improving health and well-being of service members and veterans with limb loss and/or limb deficit.

·         supports research that evaluates the comparative effectiveness of orthotic and/or prosthetic clinical interventions using patient-centric outcomes.

·         proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.

·         collaboration among academia, industry, the dod, and the va is highly encouraged, including longitudinal outcomes studies.

·         applications submitted to the fy18 oporp cta must address one or more of the fy18 oporp focus areas.

·         preclinical research is not allowed.

·         preproposal submission is required; application submission is by invitation only.

• preclinical research is not allowed.

·         funding level 1:

o   maximum funding of $350,000 for total costs (direct costs plus indirect costs)

o   maximum period of performance is 2 years.

·         funding level 2:

o   maximum funding of $2,500,000 for total costs (direct costs plus indirect costs)

• maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the oporp or other cdmrp-administered programs, please visit the cdmrp website (http://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

*call for expressions of interest: biocanrx, canada’s immunotherapy network,  is pleased to announce a call for expressions of interest to bring forward in our cycle ii application in june 2019 to the federal government’s networks of centres of excellence (nce) program. biocanrx was first awarded a 5-year funding award of $25 million from the nce program, with additional contributions coming from partners in all sectors of the economy. this first nce award ends march 31, 2020, and we are now developing our research program strategic plan as the network moves towards cycle ii.
 
this expression of interest (eoi) is your opportunity to assemble a team and propose research for consideration, and also to shape the overall renewed research program framework in alignment with the new strategic priorities identified in extensive consultation with our various stakeholder communities – our board of directors, research management committee (rmc), the cancer stakeholder alliance, and representatives from our community of network researchers.
 
while biocanrx has engaged in an in-depth consultation process, this eoi call is vital to gather feedback from our existing and potential new network members on the focus and intended outcome of our next-stage strategic plan, and to validate this approach for our renewal application, such that we are positioned to capture the best technologies and solutions to cancer immune oncology therapeutic development and implementation in the canadian context. this intake of project concepts is intended to inform biocanrx management, our board of directors, and our rmc of the range of projects and technologies within the canadian landscape which are poised to address biocanrx priorities and initiatives in the 2020-2025 funding cycle.
 
this call is open to all investigators located at canadian institutions eligible to receive peer-reviewed funding from the three federal research-granting councils (cihr, sshrc, nserc). projects in cycle ii will build upon biocanrx investments between 2015-2020, furthering the development of the most promising biological immunotherapy products and platforms, and solutions for their delivery and adoption in canada, considering critical challenges in the io development landscape in canada, and globally

genome canada, together with agriculture and agri-food canada (aafc), has announced a request for applications (rfa) for the 2018 large scale applied research project competition “genomics solutions for agriculture, agri-food, fisheries and aquaculture”. the competition aims to support projects that have the potential to provide new approaches that can improve disease and pest resistance in our crops, livestock and fish, increase our understanding of soil and aquatic microbiomes, and improve our ability to monitor and assess wild fish populations.

successful projects will use genomics to advance the sustainability, productive capacity and competitive position of the canadian agriculture and agri-food & fisheries and aquaculture sectors, and thereby strengthen canada’s economy and the wellbeing of canadians. research that examines the implications of genomics in society, such as factors that may facilitate or hinder the effective translation of research and the uptake of genomic-based applications, will also be supported as part of the competition.

the agriculture and agri-food & fisheries and aquaculture sectors have a history of using research to assess challenges and develop solutions. genomics-based approaches have the potential to predict and mitigate the effects of climate change, such as understanding the response of fisheries to climate fluctuations, identifying crops and livestock that are more resilient to temperature extremes, and by reducing methane emissions related to livestock production systems.